Date: 2015-12-21
Type of information: Milestone
Compound: Ruconest® (Rhucin® in non-European territories - conestat alfa)
Company: Pharming (The Netherlands) - Hyupjin Corporation (South Korea)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: commercialisation
Action mechanism: Ruconest® is a recombinant version of the human protein C1 inhibitor (C1INH). It is produced through Pharming’s proprietary technology in milk of transgenic rabbits.
Disease: acute angioedema attacks in patients with Hereditary Angioedema (HAE)
Details: * On March 26, 2012, Pharming Group has entered into an agreement with Hyupjin Corporation, a Seoul based Korean specialty pharma company, to commercialise Ruconest® (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea. Under the agreement, Hyupjin will drive the regulatory approval in Korea and purchase its and commercial supplies of Ruconest® from Pharming at a fixed transfer price.
Financial terms:
Latest news: * On December 21, 2015, Pharming Group and its partner, HyupJin Corporation, a Seoul based South Korean specialty pharma company, announce that Hyupjin has received the marketing authorisation for Ruconest® (recombinant human C1 inhibitor) in South Korea. Ruconest® is approved for the treatment of acute angioedema attacks in adult patients with hereditary angioedema HAE. Effectiveness was not established in HAE patients with laryngeal and oro-pharyngeal attacks. HyupJin will now seek reimbursement for Ruconest® in South Korea.
